Antibody therapy reverses biological signatures of COVID-19 progression

Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19) is key to clinical decision making and effective treatment. We study correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, M. Cyrus, Soriaga, Leah B., Gupta, Anil, Chen, Yi-Pei, di Iulio, Julia, Ledoux, Sarah, Smithey, Megan J., Cathcart, Andrea L., McKusick, Kathleen, Sun, David, Aldinger, Melissa, Alexander, Elizabeth, Purcell, Lisa, Ding, Xiao, Peppercorn, Amanda, Austin, Daren, Mogalian, Erik, Yeh, Wendy W., Shapiro, Adrienne E., Corti, Davide, Virgin, Herbert W., Pang, Phillip S., Telenti, Amalio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380250/
https://www.ncbi.nlm.nih.gov/pubmed/35977462
http://dx.doi.org/10.1016/j.xcrm.2022.100721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380250/
https://www.ncbi.nlm.nih.gov/pubmed/35977462
http://dx.doi.org/10.1016/j.xcrm.2022.100721

Ejemplares similares